Melanie Sulda

411 total citations
12 papers, 315 citations indexed

About

Melanie Sulda is a scholar working on Genetics, Pathology and Forensic Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Melanie Sulda has authored 12 papers receiving a total of 315 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 5 papers in Pathology and Forensic Medicine and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Melanie Sulda's work include Chronic Lymphocytic Leukemia Research (7 papers), Acute Lymphoblastic Leukemia research (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). Melanie Sulda is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Acute Lymphoblastic Leukemia research (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). Melanie Sulda collaborates with scholars based in Australia, New Zealand and United States. Melanie Sulda's co-authors include Chaomei Liu, Deepa Sampath, Vinay K. Puduvalli, Michael J. Keating, William G. Wierda, Karthik Vasan, Catherine A. Abbott, Bryone J. Kuss, Dimitrios Papaioannou and Jens J. Holst and has published in prestigious journals such as Blood, Clinical Cancer Research and Advances in experimental medicine and biology.

In The Last Decade

Melanie Sulda

12 papers receiving 312 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Melanie Sulda Australia	7	185	134	81	76	51	12	315
Chi Wai Wong Hong Kong	7	303 1.6×	57 0.4×	48 0.6×	130 1.7×	96 1.9×	12	447
Kathrin T. Doepfner Switzerland	6	230 1.2×	48 0.4×	51 0.6×	34 0.4×	32 0.6×	8	304
S. Bahl India	3	125 0.7×	64 0.5×	51 0.6×	26 0.3×	51 1.0×	4	217
Emanuela Roccato Italy	8	180 1.0×	49 0.4×	21 0.3×	134 1.8×	38 0.7×	8	363
Helga Simon‐Molas Netherlands	7	252 1.4×	201 1.5×	57 0.7×	87 1.1×	25 0.5×	18	389
Simon Ekman Sweden	9	180 1.0×	49 0.4×	43 0.5×	69 0.9×	10 0.2×	12	293
Gedeon Loules Greece	11	82 0.4×	44 0.3×	123 1.5×	92 1.2×	49 1.0×	14	383
Sara Koenig McLaughlin United States	4	337 1.8×	133 1.0×	39 0.5×	141 1.9×	20 0.4×	4	491
Qishui Ou China	4	220 1.2×	133 1.0×	50 0.6×	83 1.1×	19 0.4×	6	354
Ugur Aytac United States	10	144 0.8×	62 0.5×	13 0.2×	238 3.1×	28 0.5×	13	334

Countries citing papers authored by Melanie Sulda

Since Specialization

Citations

This map shows the geographic impact of Melanie Sulda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melanie Sulda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melanie Sulda more than expected).

Fields of papers citing papers by Melanie Sulda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melanie Sulda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melanie Sulda. The network helps show where Melanie Sulda may publish in the future.

Co-authorship network of co-authors of Melanie Sulda

This figure shows the co-authorship network connecting the top 25 collaborators of Melanie Sulda. A scholar is included among the top collaborators of Melanie Sulda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melanie Sulda. Melanie Sulda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Ewald, Brett, Chaomei Liu, Melanie Sulda, et al.. (2016). HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia. Clinical Cancer Research. 22(14). 3537–3549. 53 indexed citations

Ewald, Brett, Chaomei Liu, Lara Rizzotto, et al.. (2015). HDAC Inhibition Induces microRNA-182 Which Targets Rad51 Protein and Impairs Homologous Recombination Repair to Sensitize Cells to the Double Strand Break Inducing Nucleoside Analog, Sapacitabine in AML. Blood. 126(23). 3639–3639. 1 indexed citations

Mulligan, Stephen P., Devinder Gill, Paul Turner, et al.. (2014). Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL). Blood. 124(21). 4695–4695. 4 indexed citations

Mulligan, Stephen P., Devinder Gill, Paul Turner, et al.. (2014). A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity. Blood. 124(21). 3325–3325. 11 indexed citations

Mulligan, Stephen P., Devinder Gill, Paul Turner, et al.. (2012). A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study. Blood. 120(21). 436–436. 11 indexed citations

Mulligan, Stephen P., Devinder Gill, Paul Turner, et al.. (2011). 5.25 Safety and Tolerability of Oral Fludarabine, with or without Oral Cyclophosphamide and Intravenous Rituximab Therapy, in Previously Untreated Patients with Chronic Lymphocytic Leukaemia Aged 65 Years or Older: Second Interim Analysis from the Australasian Leukaemia and Lymphoma Group and CLL Australian Research Consortium CLL5 Study. Clinical Lymphoma Myeloma & Leukemia. 11. S259–S260. 1 indexed citations

Sampath, Deepa, Chaomei Liu, Karthik Vasan, et al.. (2011). Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood. 119(5). 1162–1172. 157 indexed citations

Sulda, Melanie, et al.. (2010). Clinical utility of molecular and flow cytometric markers in chronic lymphocytic leukaemia. Internal Medicine Journal. 42(2). 137–146. 3 indexed citations

Yazbeck, Roger, Melanie Sulda, Gordon S. Howarth, et al.. (2010). Dipeptidyl peptidase expression during experimental colitis in mice. Inflammatory Bowel Diseases. 16(8). 1340–1351. 39 indexed citations

10.

Mulligan, Stephen P., Devinder Gill, William Renwick, et al.. (2010). The Safety and Tolerability of Oral Fludarabine, ±oral Cyclophosphamide and Iv Rituximab Therapy In Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – Interim Analysis From the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study.. Blood. 116(21). 699–699. 5 indexed citations

11.

Sulda, Melanie, et al.. (2010). Expression and prognostic assessment of dipeptidyl peptidase IV and related enzymes in B-cell chronic lymphocytic leukemia. Cancer Biology & Therapy. 10(2). 180–189. 20 indexed citations

12.

Sulda, Melanie, Catherine A. Abbott, & Martin Hildebrandt. (2006). DPIV/CD26 and FAP in Cancer: A Tale of Contradictions. Advances in experimental medicine and biology. 575. 197–206. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact